Found 13 clinical trials
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement
urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment.
- 320 views
- 19 Dec, 2022
- 64 locations
Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)
uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment
- 18 views
- 07 Feb, 2022
- 13 locations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …
- 1032 views
- 25 Oct, 2022
- 108 locations
Study of Combined VisioCyt Test and FGFR3 Mutations on a Urinary Sample to Diagnose Bladder Tumors (URODX-FGFR3)
This study is a case-control, propsective and muticentric clinical trial, which aim to compare the specificity and sensibility of VisioCyt urinary cytological test combined with FGFR3 mutation
- 0 views
- 26 Apr, 2022
- 1 location
A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301) (SURF301)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations
- 0 views
- 21 Oct, 2022
- 3 locations
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
Calmette-Guerin (BCG) or chemotherapy instilled into the bladder. Participants in this study will have bladder cancer with a mutation in the FGFR3 gene. FGFR3 mutations are the most common genetic
- 0 views
- 04 Oct, 2022
- 7 locations
Infigratinib in Recurrent High-Grade Glioma Patients
This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3
- 0 views
- 28 Jan, 2021
- 3 locations
A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 Tablet in Adult Patients With Advanced Cholangiocarcinoma
This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.
- 0 views
- 22 Oct, 2022
- 9 locations
A Phase 1/1b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
tumors harboring FGFR2 and/or FGFR3 gene alterations.
- 5 views
- 15 Oct, 2022
- 10 locations
![A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours](/media/imagery/299628.svg)
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
, [111In]-FPI-1967, and vofatamab and the preliminary anti-tumour activity of [225Ac]-FPI-1966 in participants with FGFR3-expressing advanced, inoperable, metastatic, and/or recurrent solid tumours. Phase
- 1 views
- 04 Oct, 2022
- 1 location
- 1
- 2